NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings results on Thursday, February, 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.01. The firm earned $15.90 million during the quarter, compared to analyst estimates of $12.82 million. TherapeuticsMD had a negative return on equity of 1,047.83% and a negative net margin of 354.79%. The company's revenue was up 212.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.17) earnings per share. View TherapeuticsMD's Earnings History.

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for TherapeuticsMD.

TherapeuticsMD updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90-110 million, compared to the consensus revenue estimate of $100.15 million.

9 brokerages have issued 1-year price targets for TherapeuticsMD's shares. Their forecasts range from $3.00 to $17.00. On average, they expect TherapeuticsMD's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 383.9% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Media stories about TXMD stock have trended very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TherapeuticsMD earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 31st total of 79,360,000 shares. Based on an average trading volume of 3,670,000 shares, the short-interest ratio is currently 23.7 days. Currently, 36.6% of the shares of the company are short sold. View TherapeuticsMD's Current Options Chain.

Some companies that are related to TherapeuticsMD include Principia Biopharma (PRNB), Cambrex (CBM), Forty Seven (FTSV), Eidos Therapeutics (EIDX), Xencor (XNCR), Pacira Biosciences (PCRX), Turning Point Therapeutics (TPTX), Heron Therapeutics (HRTX), IGM Biosciences (IGMS), Tricida (TCDA), Ironwood Pharmaceuticals (IRWD), Zymeworks (ZYME), Ligand Pharmaceuticals (LGND), Arvinas (ARVN) and BELLUS Health (BLUSF).

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), Inovio Pharmaceuticals (INO), Global Blood Therapeutics (GBT) and Novavax (NVAX).

TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (6.52%), Bank of New York Mellon Corp (4.84%), Franklin Resources Inc. (3.50%), State Street Corp (2.04%), Bamco Inc. NY (1.41%) and Stifel Financial Corp (1.11%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, FMR LLC, Franklin Resources Inc., Sanders Morris Harris LLC, SG Americas Securities LLC, Raymond James & Associates and First Eagle Investment Management LLC. View Insider Buying and Selling for TherapeuticsMD.

TXMD stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Marshall Wace North America L.P., State Street Corp, Knights of Columbus Asset Advisors LLC, Goldman Sachs Group Inc., Hawk Ridge Capital Management LP and Stifel Financial Corp. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $1.86.

TherapeuticsMD has a market capitalization of $504.39 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]